Our Sponsors

The British Society for Haematology (BSH) has been bringing haematology professionals together since 1960 to transform the care our members provide to patients. With over 3,000 members worldwide, we are the largest UK haematology organisation and the only society to cover all aspects of the speciality.

Listening

Our members work together to share ideas and knowledge and to champion and strengthen haematology practice

Learning

Together we help shape the future of haematology by providing access to resources, events and education that support your professional development

Leading

Bridging the gap between research and practice, our guidelines raise the standards of clinical and patient care

The European Hematology Association promotes excellence in patient care, research, and education in hematology.

We serve medical professionals, researchers, and scientists with an active interest in hematology. We are proud to be the largest Europe-based organization connecting hematologists worldwide to support career development and research, harmonize hematology education, and advocate for hematologists and hematology. “Towards prevention, cure, and quality of life for all patients with blood disorders”. Read more about us and find out how you can benefit.

HELIOS, a growing international network funded by the COST Association, brings together over 180 experts from diverse backgrounds, including physicians, researchers, data analysts, patient advocates, ethics specialists, and more, all focused on haemoglobinopathies. Established in 2023, the network aims to enhance patient care and quality of life for those affected by these conditions by promoting collaboration to harmonize clinical and laboratory practices and management globally. At our inaugural scientific meeting, held as part of the prestigious ASCAT Conference, we will introduce participants to this new initiative, share funding and collaboration opportunities, present our initial outcomes, and feature a series of scientific presentations by our members on their ongoing work, new findings, and innovative projects.

Throughout our 125-year history, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. Our commitment to our people, partners, stakeholders and, most importantly, our patients remains as strong as it was on the first day of our journey.

Hemex Health works to reduce disparities in health outcomes by creating accurate, affordable, and easy-to-use diagnostic solutions. When diagnostics are accessible anytime, anywhere, proactive and preventive healthcare becomes possible. We help doctors and patients in the world’s most challenging clinical environments by thoughtfully designing accurate, affordable, and accessible point-of-care diagnostic solutions.

The Gazelle™ Diagnostic Device is our solution to bring diagnostics within reach. Listening to the needs of healthcare providers located in remote and challenging settings led us to identify key areas of product focus for improving diagnostic accessibility: Administration of the test is simple and requires minimal training. Results are available at the patient visit. Reports are stored digitally, or can be transmitted to a printer, laptop, or the cloud. The device is proven to work in hot, humid, and dusty conditions.

Our initial test for the platform is the Gazelle^TM Hb Variant for sickle cell disease (SCD) and beta thalassemia at point of care. Point-of-care testing is the best way to close diagnostic gap for sickle cell, according to experts and organizations such as the World Health Organization (WHO), the American Society of Hematology (ASH), and the Center for Disease Control (CDC). Gazelle makes it easy and affordable to get diagnostic results where the need is greatest.

Gazelle integrates trusted technologies into a single platform and uses AI-derived algorithms for automated interpretation of the results.

Our Gazelle Hb Variant Test is powered by our microchip electrophoresis – a miniaturized version of cellulose acetate electrophoresis. Microchip electrophoresis can both identify and quantify critical hemoglobin variants (S, A, F, A2, C/E) in a small sample of blood in just 8 minutes. Quantification enables Gazelle to identify more conditions, such as beta thalassemia, at the point of care.

Our Fluorescent Immunoassay (FIA) Technology is a precise diagnostic technique used to detect a wide variety of conditions including infectious diseases and various biomarkers. Hemex uses our proprietary AI-guided imaging to achieve improved sensitivity and quantification. Our soon-to-be-released Gazelle™ Ferritin FIA test is based on this technology.

Gazelle’s Microchip Electrophoresis and FIA technologies are versatile testing methods that can be used to diagnose a wide range of diseases. Hemex has a robust menu of tests in our pipeline.

Masters Speciality Pharma is a global pharmaceutical company that partners with innovative life-science companies to commercialise life-saving speciality medicines in emerging markets, including Latin America and the Middle East. Masters was founded in 1984 by Dr. Zulf Masters OBE, who envisioned providing everyone with access to quality, affordable medicines, prioritising the unmet needs of those in emerging markets. Masters is headquartered in the UK with offices in the USA, UAE, Malta, El Salvador, Brazil, Uruguay, and India and has over 90 employees. The company has over 39 years of experience supporting healthcare providers and their patients, supplying medicines to hospitals, clinics, and government organisations in over 75 countries.

The National Haemoglobinopathy Panel (NHP) is a professional multidisciplinary group of health professionals commissioned by NHS England to facilitate harmonisation and improvement of Haemoglobinopathy services across England, for the benefit of Sickle Cell Disorder, Thalassaemia and Rare Inherited Anaemia patients.

Our mission is broad and wide ranging but will always be focused on niche products, from personalised medicines and rare diseases, to novel technologies and therapies.

With in-house clinical expertise we have in-depth knowledge of current deficiencies in the treatment of rarer diseases, with a particular focus on creating liquid versions of existing medicines for precision dosing and use in paediatrics.

Our formulation team have successfully created stable, liquid versions of several existing medicines, now brought to market, and continue to work on our pipeline.

Homepage - Nova Knowledge Centre (nova-knowledge.co.uk)